RxDoctor Payments Data

Renee Katter, PA

Physician Assistant · Chubbuck, IDNPI 1053502955

Payments from drug & device makers

$4,008in general payments, 2019–2025

Across 227 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$800
  • Teva Pharmaceuticals USA, Inc.$572
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$383
  • Otsuka America Pharmaceutical, Inc.$367
  • Alkermes, Inc.$267
  • Vanda Pharmaceuticals Inc.$250
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,75994%
  • Education$2496%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,008 in reported general payments places this provider in the 90th percentile of 1,027 physician assistant providers in Idaho.

See all physician assistant providers in Idaho

Medicare billing

Part B allowed, 2024
$21,188
Medicare patients
42
Services billed
242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl145$202,480
TrintellixVortioxetine Hydrobromide105$72,623
AuvelityDextromethorphan Hbr/Bupropion48$62,411
Invega SustennaPaliperidone Palmitate20$61,730
RexultiBrexpiprazole39$60,026
AustedoDeutetrabenazine12$56,091
LybalviOlanzapine/Samidorphan Malate31$49,438
BelsomraSuvorexant52$22,155
CaplytaLumateperone Tosylate12$19,061
DayvigoLemborexant41$12,946
Paliperidone ErPaliperidone41$11,522
Jornay PmMethylphenidate Hcl22$9,151
Aripiprazole78$9,070
Vilazodone Hcl117$8,207
Lisdexamfetamine Dimesylate39$8,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Viibryd$800$209,759167 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$141$77,518118 claims
Axsome Therapeutics, Inc.Auvelity$195$62,41148 claims
Johnson & JohnsonInvega Sustenna$35$61,73020 claims
Otsuka America Pharmaceutical, Inc.Rexulti$367$60,02639 claims
Teva Pharmaceuticals USA, Inc.Austedo$572$56,09112 claims
Alkermes, Inc.Lybalvi$267$49,43831 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$383$19,06112 claims
Eisai Inc.Dayvigo$43$12,94641 claims
Ironshore Pharmaceuticals Inc.Jornay Pm$156$9,15122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,027 physician assistant providers in Idaho.

Other physician assistant in Chubbuck

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →